I became a believer in virtual care the year my dad needed three specialists in two months and lived ninety minutes from the nearest one. Half of those appointments ended up happening on a screen, and they were just as useful — minus the drive, the parking, and the waiting room. But that experience also taught me something the hype machine skips: the technology working well for patients and the stock working well for investors are two very different things.
So here’s my honest framing before we go further. Telehealth stocks are shares in companies that deliver or enable healthcare remotely — virtual doctor visits, mental health platforms, remote patient monitoring, and the software tying it together. They draw growth investors because virtual care tackles real problems like provider shortages and access gaps, but the sector has been brutal on shareholders who paid pandemic prices. Promise and price are not the same thing.
What most coverage misses is that “telehealth stock” lumps together businesses that barely resemble each other. A direct-to-consumer virtual clinic, a physician-network advertising platform, and a remote-monitoring device maker are all “telehealth” — yet they make money in completely different ways and break for completely different reasons. So I’ll sort the space by how each company actually earns its keep, and point out where the durable compounders and the value traps tend to hide.
Why I still pay attention to telehealth stocks
The bull case starts with a problem that isn’t going anywhere: there aren’t enough doctors, and the ones we have aren’t where the patients are. Virtual care stretches a limited supply of clinicians across more people, more geographies, and more hours of the day. That’s not a fad that fades when the pandemic headlines do — it’s a structural mismatch between healthcare demand and supply that gets worse as the population ages.
Cost is the second pillar. A virtual visit is often cheaper to deliver than an in-person one, and a lot of routine care — prescription refills, follow-ups, mental health check-ins, chronic disease management — simply doesn’t require a physical exam. Insurers and employers have noticed. When a model saves money for the people writing the checks, it tends to stick around, and that’s a tailwind I weigh alongside the broader move toward technology-driven medicine I cover in the Digital Health Stocks space.
Then there’s the shift from one-off visits to ongoing relationships. The companies I find most interesting aren’t selling a single video call — they’re managing a patient’s diabetes or depression month after month, with recurring revenue and a reason to stay engaged. That continuity is what turns a transactional app into a real business. The thesis is genuinely strong. The trouble, as always, is what you pay for it.
The telehealth landscape at a glance
Here’s the map I keep in my head. The sector has split into distinct models, each making money differently and carrying its own flavor of risk. This table lays out the major types, why each one matters, and the trap that tends to bite. Treat it as a starting frame rather than gospel — the lines blur, and the strongest players are stretching across more than one lane.
| Model | How it makes money | Why it matters | Main risk to watch |
|---|---|---|---|
| Pure-play virtual care | Visit fees, subscriptions, employer contracts | Direct exposure to the virtual-care shift | Churn, thin margins, fierce competition |
| Physician network platforms | Pharma marketing, hiring, B2B services | Diversified revenue, less consumer-demand sensitivity | Ad-spend cyclicality |
| Remote patient monitoring | Connected devices plus recurring data fees | Sticky, reimbursed, tied to chronic care | Hardware economics, reimbursement shifts |
| Hybrid / retail care | Blends physical clinics with virtual visits | Combines real estate scale with convenience | Execution and integration risk |
| Enabling software | Licenses telehealth tools to health systems | Picks-and-shovels exposure to the whole field | Long sales cycles, platform competition |
Notice that the “best” model depends on what kind of investor you are and what’s already in your portfolio. The consumer-facing names grab the headlines and the wild price swings; the B2B and monitoring businesses are often steadier and less understood. Let me walk through the segments that matter most.
Pure-play virtual care: the most obvious bet, and the most punishing
If you ask someone to name a telehealth stock, they’ll almost always name a pure-play — a company whose whole identity is delivering care over a screen. Teladoc Health (TDOC) is the name most people reach for, offering virtual primary care, mental health, and chronic care management. Hims & Hers Health (HIMS) took a different angle, building a direct-to-consumer brand around specific conditions and prescription fulfillment.
This is where the opportunity and the pain both concentrate. The opportunity is obvious: these companies sit directly in front of the virtual-care wave. The pain is just as real. Many rode an enormous pandemic surge, repriced at sky-high valuations, then watched their stocks collapse as visit volumes normalized and competition flooded in. Some of those drawdowns ran brutally deep — check current data before you assume the bottom is in.
My honest take on this group: the businesses can be good, but the unit economics matter more than the story. I want to see customers who stay, spend more over time, and don’t cost a fortune to acquire in the first place. Direct-to-consumer health is an expensive place to win attention, and a company burning cash to buy growth is not the same as a company building a durable franchise. Separate the two before you buy.
Physician networks and enabling software: the quieter way to play it
Here’s the corner most people overlook. Some of the most resilient businesses in this field don’t deliver care to you at all — they sell to the people who do. Doximity (DOCS) runs a physician network whose revenue comes largely from pharmaceutical marketing, hiring tools, and other B2B services, with telehealth features layered on top. That diversification makes it far less hostage to consumer visit volumes than a pure-play clinic, and it has tended to be a genuinely profitable business rather than a cash-burning one.
Enabling software is the other quiet lane — the picks-and-shovels play. Instead of competing for patients, these companies license the technology that hospitals and clinics use to run their own virtual programs. The financial DNA looks a lot like enterprise software: recurring licenses, sticky integrations, long sales cycles. It rides the entire telehealth wave without betting on any single consumer brand, which is exactly why I track it next to the rest of the healthcare-technology names in my list of the Best Healthcare Growth Stocks.
The trade-off with these B2B models is excitement — or the lack of it. They rarely double in a quarter, and ad-driven names carry their own cyclicality when pharma marketing budgets tighten. But for an investor who got burned chasing a pure-play to the moon and back, the steadier cash flows and real profitability of a network or software business can be a welcome change of pace.
Remote monitoring, hybrid care, and where the lines blur
Remote patient monitoring might be the most underappreciated piece of all. These are the connected devices — glucose monitors, blood pressure cuffs, cardiac sensors — that track patients between visits and feed data back to care teams. Dexcom (DXCM) sits at the center of this with continuous glucose monitoring, and while you might file it under medical devices rather than telehealth, the line between the two is fading fast. The data stream is recurring, often reimbursed, and tied directly to chronic disease management, which is where a lot of healthcare spending actually goes. I dig into that overlap more in my coverage of the Best Medical Device Stocks.
Hybrid and retail care is the model I think has the most staying power, even if it’s the least glamorous. The idea is simple: combine physical locations with virtual visits so patients get whichever is appropriate. Large pharmacy and retail health players — think the CVS Health (CVS) type of company — are stitching virtual care onto an existing footprint of stores, clinics, and pharmacies. The scale advantage is real; the catch is execution, because integrating virtual and physical care across a sprawling organization is genuinely hard and has tripped up well-funded efforts before.
What ties this section together is convergence. Devices, software, virtual visits, and physical clinics are bleeding into one another, and the same company increasingly shows up in several of my watchlists at once. That’s worth noticing — it’s easy to think you’re diversified across “telehealth, devices, and digital health” when you actually own three slices of one trend.
How I actually evaluate telehealth stocks
Knowing the models is half the job; judging an individual company is the other half. The flashy ones often look expensive and the cheap ones are frequently cheap for a reason, so here’s the framework I run through.
First, the quality of the revenue. Is it recurring and growing per customer, or is it a parade of one-time visits that have to be re-won every quarter? I look hard at retention and whether existing patients or clients spend more over time — the cleanest signal that a business is sticky rather than a novelty. Second, the path to profitability. A painful number of telehealth names grew fast while bleeding cash, and I want a credible march toward real free cash flow, not top-line growth propped up by marketing spend and stock-based pay.
Third, where the moat actually lives. Is it a brand, a data advantage, an integration into hospital workflows, a regulatory edge? And then valuation — the discipline most investors skip, and the one this sector punished hardest. A decent company bought at a pandemic-era price was still a terrible investment, as a lot of people learned the expensive way. The same valuation habits I apply across my whole portfolio show up in my list of the Best Growth Stocks to Buy in 2026. I’d rather buy a solid virtual-care business during a moment of pessimism than a perfect one during a mania.
The risks I never wave away
I like the long-term thesis, but I’d be doing you a disservice if I soft-pedaled the risks — this is one of the few growth themes that has already handed investors a real beating. Reimbursement is the big one. A lot of telehealth’s growth was unlocked by temporary pandemic-era rules that loosened how virtual care gets paid for, and if regulators tighten those, the economics can shift overnight. In this sector, a policy decision in Washington can matter as much as anything in the company’s control.
Competition is the second threat, and it’s relentless. Traditional health systems built their own virtual capabilities, big retail and pharmacy players muscled in, and the cloud giants keep circling healthcare. A standalone virtual clinic can find itself squeezed from every direction at once. Profitability is the third — too many of these companies have promised a path to durable earnings that kept slipping, and hope is not a financial model.
None of this kills the thesis. It argues for diversification, real discipline on price, and position sizes you can hold through a bad stretch. Because telehealth shares so many drivers with the rest of healthcare technology, it’s easy to end up more concentrated in one theme than you realize — so I weigh my virtual-care exposure against adjacent bets like mRNA Technology Stocks before adding to any single corner of the sector.
Frequently asked questions
Are telehealth stocks a good long-term investment?
They can be, for investors who can stomach volatility and choose carefully. The long-term demand picture is real — provider shortages, access gaps, and cost pressure all favor virtual care. But the sector has already punished shareholders who paid pandemic prices, and many names still need to prove durable profitability. I treat the strongest telehealth stocks as a selective holding, not a basket buy. Check current data before investing.
Why did telehealth stocks crash after the pandemic?
Two forces hit at once. Visit volumes that spiked during lockdowns normalized as life reopened, so growth slowed sharply. At the same time, many of these stocks had been priced for that surge to continue forever. When reality fell short of those expectations, valuations reset hard, and some names fell a long way from their highs. The drops reflected expectations as much as the underlying businesses.
What is the difference between pure-play and hybrid telehealth?
A pure-play telehealth company delivers care almost entirely over a screen — virtual visits, prescriptions, mental health, chronic care. A hybrid model blends virtual care with physical locations like clinics and pharmacies, so patients get whichever fits. Pure-plays offer the most direct exposure to the virtual shift but face fierce competition; hybrids gain scale and convenience but carry real execution risk integrating the two.
Is telehealth still growing or has it peaked?
The pandemic spike clearly peaked, but underlying adoption hasn’t reversed — it settled at a far higher baseline than before 2020 and keeps expanding in areas like mental health, chronic care, and remote monitoring. So the explosive phase is over, while the structural growth phase continues. The realistic picture is steadier, durable expansion rather than another vertical surge. Confirm current figures before relying on any single estimate.
Should I buy individual telehealth stocks or a healthcare fund?
Both have a place. A broad healthcare or digital-health fund gives you diversification and spares you single-name blowups, which matter a lot in a sector this volatile. Individual stocks offer the chance to outperform if you do the research and respect the entry price. I run a core-and-satellite approach: a diversified base, with researched individual names around it where I have genuine conviction.
The Bottom Line
Telehealth is a durable, important theme that has been a humbling place to invest, and both of those things are true at once. “Telehealth stock” hides several very different businesses under one word, so get specific. Understand how each company actually makes money, respect the reimbursement and competition risks, anchor your exposure in businesses with sticky revenue and a real path to profit, and never let a compelling story talk you into paying any price. Do that, size the volatility honestly, and the structural tailwinds behind virtual care can still compound a great deal on your behalf.
Last updated: June 2026. Figures are approximate and change — confirm current data before investing. Educational only, not individual investment advice.
